J&J Shelves Planned Rebate Model for 340B Drug Discounts
- October 04, 2024
Johnson & Johnson (J&J) will not move ahead with a new rebate-model policy for obtaining discounts on the company’s two drugs—Stelara and Xarelto—under the 340B program, the company told the Health Resources and Services Administration (HRSA) in a September 30 letter.
ARTICLE TAGS
You must be logged in to access this content.